Exacerbated synucleinopathy in mice expressing A53T SNCA on a Snca null background

Area of Science:

• Neuroscience
• Genetics
• Molecular Biology

Background:

• Alpha-synuclein aggregates form Lewy bodies, a hallmark of Parkinson's disease (PD).
• A specific human alpha-synuclein mutation (Ala53Thr) causes PD, but wild-type mice do not spontaneously develop the disease.
• Differences between human and mouse alpha-synuclein may confer resistance in mice.

Purpose of the Study:

• To investigate the protective role of endogenous mouse alpha-synuclein against human mutant alpha-synuclein toxicity.
• To understand the impact of species-specific alpha-synuclein variations on Parkinson's disease pathogenesis.

Main Methods:

• Generation of transgenic mice expressing human Ala53Thr alpha-synuclein.
• Cross-breeding transgenic mice with mice lacking endogenous alpha-synuclein.
• Phenotypic analysis of motor function and neuropathology in resulting mouse models.

Main Results:

• Mice expressing only human alpha-synuclein developed a progressive neuronopathy with limb weakness and paralysis.
• Neuropathology included motor neuron damage and Wallerian degeneration, likely due to high transgene expression in the ventral spinal cord.
• Mice expressing both human and mouse alpha-synuclein exhibited milder phenotypes compared to those with only human alpha-synuclein.

Conclusions:

• Endogenous mouse alpha-synuclein confers significant protection against the neurotoxic effects of human mutant alpha-synuclein.
• This suggests that mouse alpha-synuclein acts as a barrier to the development of severe pathology seen in human Parkinson's disease.
• Understanding these species-specific differences can inform therapeutic strategies for Parkinson's disease.